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Abstract
Background: The identification of genes responsible for human inherited diseases is one of the most challenging
tasks in human genetics. Recent studies based on phenotype similarity and gene proximity have demonstrated
great success in prioritizing candidate genes for human diseases. However, most of these methods rely on a single
protein-protein interaction (PPI) network to calculate similarities between genes, and thus greatly restrict the scope
of application of such methods. Meanwhile, independently constructed and maintained PPI networks are usually
quite diverse in coverage and quality, making the selection of a suitable PPI network inevitable but difficult.
Methods: We adopt a linear model to explain similarities between disease phenotypes using gene proximities that
are quantified by diffusion kernels of one or more PPI networks. We solve this model via a Bayesian approach, and
we derive an analytic form for Bayes factor that naturally measures the strength of association between a query
disease and a candidate gene and thus can be used as a score to prioritize candidate genes. This method is
intrinsically capable of integrating multiple PPI networks.
Results: We show that gene proximities calculated from PPI networks imply phenotype similarities. We
demonstrate the effectiveness of the Bayesian regression approach on five PPI networks via large scale leave-one-
out cross-validation experiments and summarize the results in terms of the mean rank ratio of known disease
genes and the area under the receiver operating characteristic curve (AUC). We further show the capability of our
approach in integrating multiple PPI networks.
Conclusions: The Bayesian regression approach can achieve much higher performance than the existing CIPHER
approach and the ordinary linear regression method. The integration of multiple PPI networks can greatly improve
the scope of application of the proposed method in the inference of disease genes.
Background
Inference of genes responsible for human inherited dis-
eases has been one of the major tasks in modern human
and medical genetics. Traditionally, associations between
diseases and genes are pinpointed through statistical
methods such as family-based linkage analysis and
population-based association studies [1], which have
been demonstrating remarkable successes in mapping
disease genes. However, linkage analysis can only associ-
ate diseases with genetic regions that typically contain
dozens to hundreds of genes, and association studies
usually require carefully selected candidate genes that
are biologically related to the disease of interest, making
computational inference of causative genes from posi-
tional candidates and the selection of functional candi-
dates indispensible [2,3].
Most existing computational methods for inferring
causative genes from candidates are formulated as a
one-class novelty learning problem that is usually solved
with the guilt-by-association principle, which suggests to
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quantify the strength of association between a query dis-
ease and a candidate gene, and then rank candidate
genes according to their scores to facilitate the selection
of susceptibility genes [4]. For this purpose, various
genomic data, including protein sequences [5,6], gene
expression profiles [6-8], functional annotations [6,8-11],
literature descriptions [6,7,12], protein interactions
[6,8,13,14], and many others [15] have been employed
to characterize similarities between genes, with the
assumption that genes similar in one or more character-
istics are usually similar in their functions, and thus are
likely to be associated with the same disease. Recent stu-
dies have also shown the modular nature of human
genetic diseases [15-23], which suggests that diseases
share common clinic characteristics are often caused by
functionally related genes [24]. With this understanding,
various methods have been proposed to utilize pheno-
type similarity and gene proximity for the inference of
causative genes for human inherited diseases [14,25-27].
It has been shown that the Pearson’s correlation coeffi-
cient of similarities between phenotypes and closeness of
genes in a single protein-protein interaction (PPI) network
can be used as a concordance score to facilitate the priori-
tization of candidate genes [25]. However, PPI networks
are far from complete. For example, the Human Protein
Reference Database (HPRD) [28], as one of the most com-
prehensive protein interaction databases, only covers less
than half of human protein-coding genes. Therefore, rely-
ing on a single PPI network to infer disease genes will
restrict the scope of application of such methods. Mean-
while, there have been a few protein interaction databases
constructed and maintained independently. These data-
bases are often quite diverse in coverage and quality, mak-
ing the selection of a suitable PPI network inevitable.
Moreover, although the naïve thinking of combining all
available protein interactions into a single large network is
straightforward, performance of methods based on such a
combined network is questionable [25].
With these considerations, we propose a Bayesian
regression approach that can be used with either a single
PPI network or multiple networks to prioritize candidate
genes. We adopt a linear model to explain disease simi-
larity using gene proximity, and we solve this model via a
Bayesian approach, which yields an analytic form of
Bayes factor for measuring the strength of association
between a query disease and a candidate gene. We then
use Bayes factors as scores to prioritize candidate genes.
We show the validity of assumptions of this approach,
and we demonstrate the effectiveness of this approach on
five PPI networks via large scale leave-one-out cross-
validation experiments and comprehensive statistical
analysis. We further show the capability of our approach
in integrating multiple PPI networks.
Methods
Data sources
We propose to infer disease genes using gene proximity
profiles derived from protein-protein interaction (PPI)
networks, a phenotype similarity profile calculated using
text mining technique, and known associations between
disease phenotypes and genes extracted from the Online
Mendelian Inheritance in Man (OMIM) database.
There have been a few PPI networks with diverse cov-
erage and quality. In our study, we adopt five widely-
used PPI networks to calculate gene proximity profiles.
First, the Human Protein Reference Database (HPRD)
contains human protein-protein interactions that are
manually extracted from the literature by expert biolo-
gists [28]. After removing duplications and self-linked
interactions, we extract from release 8 of this database
36,634 interactions between 9,470 human genes. Second,
the Biological General Repository for Interaction Data-
sets (BioGRID) contains protein and genetic interactions
of major model organism species [29]. We extract from
version 2.0.63 of this database 29,558 interactions
between 9,043 human genes. Third, the Biomolecular
Interaction Network Database (BIND) contains both
high-throughput and manually curated interactions
between biological molecules [30]. From this database,
we collect 14,955 interactions between 6,089 human
genes. Fourth, the IntAct molecular interaction database
(IntAct) contains protein-protein interaction derived
from literature [31]. From this database, we collect
30,030 interactions between 6,775 human genes. Finally,
the Molecular INTeraction database (MINT) contains
information about physical interactions between pro-
teins [32]. From this database, we collect 15,902 interac-
tions between 7,200 human proteins. Details about these
five PPI networks are given in Table 1.
The phenotype similarity profile, which is obtained
from an earlier work of van Driel et al [21], is repre-
sented as a matrix of pair-wise similarities between
human disease phenotypes. Briefly, van Driel et al ana-
lyzed the full-text and clinical synopsis fields of all
OMIM records, and used the anatomy and the disease
sections of the medical subject headings vocabulary
(MeSH) to extract terms from the OMIM records [21].
Table 1 Summary of the five protein-protein interaction
networks
Genes Interactions Seed
diseases
Seed
genes
Seed
associations
HPRD 9,470 36,634 1,590 1,440 2,466
BioGRID 9,043 29,558 1,412 1,247 2,166
BIND 6,089 14,955 1,016 811 1,442
IntAct 6,775 30,030 1,094 933 1,622
MINT 7,200 15,902 889 677 1,231
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type using a feature vector that was composed of stan-
dardized and weighted phenotypic feature terms and
further calculated a similarity score for a pair of pheno-
types as the cosine of the angle of their feature vectors.
Finally, they obtain a phenotype similarity profile that
contains pair-wise similarity scores for 5,080 OMIM
diseases.
Known associations between disease phenotypes and
genes are extracted from BioMart [33]. For genes in
HPRD, we obtain 2,466 associations between 1,590 dis-
eases and 1,440 genes. For BioGRID, we obtain 2,166
associations between 1,412 diseases and 1,247 genes. For
BIND, we obtain 1,442 associations between 1,016 dis-
eases and 811 genes. For IntAct, we obtain 1,622 asso-
ciations between 1,094 diseases and 933 genes. For
MINT, we obtain 1,231 associations between 889 dis-
eases and 677 genes. We also summarize the above
information in Table 1.
Bayesian linear regression
We adopt a linear regression model to explain disease
similarities in the phenotype similarity profile using
gene similarities in one or more gene proximity profiles,
and we solve this regression model via a Bayesian
approach [34]. For a clear presentation, we first derive
this method using a single gene proximity profile and
then extend this model to include multiple profiles.
A gene proximity profile contains pair-wise similarity
measure of every two genes and is calculated as the
diffusion kernel of the underlying PPI network. Given
an e t w o r ko fn nodes, represented by an adjacency
matrix A, we calculate the Laplacian of the network as
L=D– A and the diffusion kernel as Z = e
-gL,w h e r e
D is a diagonal matrix containing node degrees, and
0< g < 1 a free parameter that controls the magnitude
of diffusion. With the kernel Z =( zij)n×n,w ed e f i n et h e
proximity of two genes i and j as the corresponding
element zij in the kernel.
Let ydd′ denote the similarity score between a query
disease d and another disease d′.W ed e f i n et h ep h e n o -
type similarity vector for disease d as
y d
T
dd dd dd yy y
m = (, , ) ,
12  , i.e., the similarities between
disease d and all m diseases d1,d2,…,dm in the pheno-
type similarity profile. Let Zgg′ denote the proximity
score between genes g and g′ i nt h eg e n ep r o x i m i t y
profile and G(d)t h es e to fg e n e sk n o w na sa s s o c i a t e d
with disease d. We define the proximity between gene
g and disease d as the summation of proximity scores
between gene g and all genes known as associated with
disease d, denoted by xz gd gg gG d
= ′ ′∈ ∑ () .W ef u r t h e r
define the gene proximity vector for gene g as
x g
T
gd gd gd xx x
m = (, , ) ,
12  , i.e., the proximities
between gene g and all diseases d1,d2,…,dm in the phe-
notype similarity profile.
We then explain the phenotype similarity vector for
disease d using gene proximity vectors of all genes that
are associated with the disease via a linear regression
model
yX =+  ,
where y = yd i st h er e s p o n s ev e c t o r ,X the design
matrix, b the coefficient vector, and   =… (, ) , 1 m
T
the residual vector. For disease d associated with a total
of p genes, the design matrix X has p+1 columns, with
the first column being 1s for the purpose of incorporat-
ing the intercept.
We solve this model using a Bayesian approach [34]
and use the resulting Bayes factor to measure the
strength of evidence for a candidate association. For the
alternative model, we assume that y conditional on X is
subject to a normal distribution, as
y Normal XX I |, , ~ ( , ) ,  
22
with residuals independent and identically distributed,
following normal density with mean 0 and variance s
2.
We set conjugate prior distributions for b and s
2,a s
     
22 2 ~-( , ) | ~( ) , , Inverse Gamma Normal  and  Σ
where    =… (, ) ,, 01 p
T is composed of prior
means, and s
2Σ prior variances with Σ= … diag( , ) ,,   0
2
1
22
p
being a diagonal matrix. The joint distribution of all ran-
dom quantities y, b,a n ds
2 is then given as
py X py X p p (, | ( | , ( | ( | ,) , ) , , ) , ) .       
22 2 2 =Σ
Integrating out b and s
2, we obtain the marginal like-
lihood of y given X as
pyX
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On the other hand, for the null model, where y is
independent of X, the marginal likelihood of y can be
derived in a similar way, as
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Then, the Bayes factor is calculated as the ratio of the
marginal likelihood under the alternative and the null
hypotheses, respectively, as
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Following literature [34], we will use the parameter set-
ting  === = 00 01 0 0
10 ,, ,      (as +∞ in calcula-
tion) and si = 1 (for i ≥ 1) throughout this paper, though
a grid search for other values of si shows that the method
is quite robust to this parameter. It has been shown that
the parameter g should take a small value [35-37]. In our
study, we perform a grid search for this parameter and
find results are quite robust when 0.1 ≤ g ≤ 0.3. Therefore
we will use g = 0.2 throughout this paper.
Obviously, a larger Bayes factor indicates a better
exhibition of the linear relationship between the disease
similarity and the gene proximity. With this understand-
ing, we propose the following schemes to prioritize can-
didate genes. First, given a query disease and a set of
candidate genes, we calculate a Bayes factor for each
candidate gene, with the assumption that the gene is the
only one associated with the query disease. Then, we
rank candidate genes in non-increasing order according
to their Bayes factors. This scheme mimics the situation
in which we aim at inferring associations between genes
and a “novel” disease that has yet not been previously
studied. Second, for a disease that has been previously
studied (and thus already has some genes associated),
we can choose to calculate Bayes factors for candidate
genes with the inclusion of the genes that are already
known to be associated with the disease. This scheme is
more suitable for inferring associations between genes
and a disease that has been previously studied (and thus
has known associated genes).
In the case that multiple gene proximity profiles cal-
culated from multiple PPI networks are available, we
extend the regression model by incorporating additional
gene proximity vectors into the design matrix. Suppose
that disease d is associated with p genes, and q gene
proximity profiles are available, the design matrix X will
have pq + 1 columns, with column 1 for the intercept,
columns 2 to p + 1 for the first profile, columns p +2
to 2p + 1 for the second profile, and so on. With this
extension, all the above reasoning remains unchanged.
Validation methods and evaluation criteria
We adopt two large scale leave-one-out cross-validation
experiments to test how well the Bayesian regression
approach performs in recovering known associations
between diseases and genes. In the validation of random
controls, we prioritize genes that are known as asso-
ciated with diseases against randomly selected genes. In
each run of the validation, we select an association
between a gene and a disease, assume that the associa-
tion is unknown, and prioritize the gene against a set of
99 randomly selected control genes. In the validation of
simulated linkage intervals, we simulate the real situa-
tion of identify disease genes by prioritizing genes that
are known as associated with diseases against genes that
are located around the disease genes. In each run of the
validation, we select an association between a gene and
a disease, assume that the association is unknown, and
prioritize the gene against a set of control genes that are
located in 10Mbp upstream and downstream around
this gene. In both experiments, we adopt the first
scheme to mimic the situation of inferring associations
between genes and novel diseases, for the purpose of
achieving a more strict validation.
In each of the above leave-one-out cross-validation
experiments, we repeat the validation run for every
known association between a disease and a gene, obtain-
ing a number of ranking lists. We further normalize the
ranks by dividing them with the total number of candi-
date genes in the ranking list to obtain rank ratios and
derive two criteria to measure the performance of a
prioritization method. The first criterion is mean rank
ratio, which is simply the average of rank ratios over all
disease genes in a cross-validation experiment. This cri-
terion provides a summary of the ranks of all genes that
are known as associated with diseases, and the smaller
the mean rank ratio, the better a method. The second
criterion is AUC, the area under the receiver operating
characteristic curve (ROC). Given a list of rank ratios
and a predefined threshold, we define the sensitivity as
the percentage of disease genes that are ranked above
the threshold and the specificity as the percentage of
control genes that are ranked below the threshold. Vary-
ing the threshold values, we are able to plot a ROC
curve, which shows the relationship between sensitivity
and 1-specificity. Calculating the area under the ROC
curve, we obtain the AUC score, which provides an
overall measure for the performance of a prioritization
method.
Results
Gene proximity implying phenotype similarity
The proposed approach for inferring disease genes is
based on the assumption that phenotypically similar dis-
eases are caused by functionally related genes that are
usually proximal in a PPI network. Moreover, we
assume the existence of a linear relationship between
similarities of diseases and proximities of genes that are
associated with the diseases. In order to validate this
Zhang et al. BMC Bioinformatics 2011, 12(Suppl 1):S11
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between 1,590 diseases and 1,440 genes, calculate Bayes
factors for these disease genes, and run a Wilcoxon
signed rank test to check whether the resulting Bayes
factors are significantly greater than 1 (the random
case). Results show that the p-value is smaller than
2.2E-16, indicating that the similarities of diseases have
a linear relationship with the proximities of disease
genes.
To further substantiate this point, we perform a series
of permutations towards disease-disease, disease-gene,
and gene-gene relationships. First, we break disease-
disease relationship by permuting the phenotype similar-
ity profile. Second, we break disease-gene relationship by
two methods: (1) permuting disease-gene associations
and (2) replacing disease genes in known disease-gene
associations with randomly selected genes. Third, we
break gene-gene relationship by permuting connections
in the underlying protein-protein interaction network
while keeping node degrees and recalculating the diffu-
sion kernel. For each of the above permutations, we cal-
culate Bayes factors of disease genes and present the
results in Figure 1, from which we can clearly see that
the median of Bayes factors based on the original data is
much higher than those using permuted relationships.
We also perform similar studies using data extracted
from BioGRID, BIND, IntAct, and MINT, and we obtain
similar results as HPRD. From these comprehensive stu-
dies, we conclude that similarities between diseases can
be explained using network proximities of genes that
are associated with the diseases. In other words, gene
proximity implies phenotype similarity.
Prioritization with individual PPI networks
We design a series of large scale leave-one-out cross-
validation experiments to show the validity and
effectiveness of the Bayesian regression approach on
individual PPI networks. As described in the method
section, in each run of the validation procedure, we
prioritize candidate genes according to the Bayes fac-
tors against two control sets, random controls and
linkage intervals, with the performance being evaluated
by mean rank ratios and AUC scores. Results are
s h o w ni nT a b l e2a n dF i g u r e2 .
From Table 2, we see that the mean rank ratios
obtained using the five PPI networks are all below 0.17,
and the AUC scores are all above 0.83, suggesting the
effectiveness of the Bayesian regression approach. The
best performance are obtained using HPRD, with which
the mean rank ratios against random controls and link-
age intervals are 0.1349 and 0.1353, respectively, and the
AUC scores are 0.8738 and 0.8720, respectively. From
Figure 2, we see that the ROC curves of the HPRD data
set are above those of the other data sets, suggesting
that the performance on HPRD is superior over that of
the others. To understand this observation, we perform
one-sided Wilcoxon rank sum test against the hypoth-
esis that Bayes factors of disease genes for the HPRD
data set are greater than those for the other data sets.
Results show that Bayes factors of disease genes for the
HPRD data set are indeed greater than those of Bio-
GRID (p- v a l u e = 4 . 7 E - 2 ) ,B I N D( p-value=2.6E-3), IntAct
(p-value=1.9E-5), and MINT (p-value=2.5E-5). We
therefore conjecture that the performance of the
proposed method depends on how well the linear
Figure 1 Bayes factors of the original and permuted data. “original”, “permuted PPS”, “permuted seed”, “random seed”, “permuted PPI”
denote the results obtained using original data, permuting phenotype similarity profile, permuting disease-gene associations, replacing disease
genes in disease-gene associations with randomly selected genes, and permuting connections in the protein-protein interaction network,
respectively.
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mity exhibits.
To further demonstrate the effectiveness of the pro-
posed approach, we repeat the same leave-one-out cross-
validation experiments using the existing CIPHER
approach [25], which relies on Pearson’s correlation coef-
ficient between the disease similarity vector and the gene
proximity vector to prioritize candidate genes. We com-
pare the results of these two approaches in Figure 3,
from which we see clearly that the Bayesian regression
approach in general achieves lower mean rank ratios and
higher AUC scores in all the five data sets. For example,
when performing cross-validation for linkage intervals
using the HPRD data set, the CIPHER approach achieves
a mean rank ratio of 0.1746 and an AUC score of 0.8313,
whereas the Bayesian approach achieves a mean rank
ratio of 0.1353 and an AUC score of 0.8720, suggesting
an obvious improvement over the CIPHER approach.
Note that the CIPHER method calculates gene proximity
matrix by applying a Gaussian kernel to the shortest path
distance matrix of the underlying network. We also try to
use the diffusion kernel matrix as the gene proximity
matrix and find the difference is not obvious. These
results strongly suggest that the Bayesian regression
approach is superior over the CIPHER approach in prior-
itizing candidate genes.
It is also of interest to compare the Bayesian approach
with the ordinary linear regression method. For this pur-
pose, we implement another method that relies on R
2, the
coefficient of determination, to prioritize candidate genes.
We repeat the leave-one-out cross-validation experiments
for this method and present the results in Figure 3, from
which we see clearly that the Bayesian regression approach
in general achieves higher performance than the ordinary
regression method in terms of both mean rank ratios and
AUC scores in all the five data sets.
Prioritization with the integration of multiple PPI
networks
The coverage of a single PPI network is in general not
high. Even the largest HPRD network covers only 9,470
genes, less than half of known human protein-coding
genes. We therefore propose to use the Bayesian regres-
sion approach to integrate multiple PPI networks, for
the purpose of improving the coverage.
By taking the union of genes on individual PPI net-
works, we obtain 15,644 human genes. Focusing on
these genes, we extract from BioMart 2,708 associations
between 1,752 diseases and 1,621 genes. With this data
set, we repeat the leave-one-out cross-validation experi-
ments using individual gene proximity profiles and pre-
sent the results in Figure 4. Note that in this procedure,
we set the proximity of two genes to zero (minimum
proximity) if any of the two genes is absent from the
underlying network. We observe that the performance
on individual proximity profiles drops dramatically in
this larger data set (in comparison with Table 2), simply
because each PPI network covers only a fraction of
Table 2 Performance of the Bayesian regression
approach on individual data sources
Random Control Linkage Interval
Mean Rank
Ratio (SD)
AUC (SD) Mean Rank Ratio AUC
HPRD 0.1349 (0.0004) 0.8738 (0.0004) 0.1353 0.8720
BioGRID 0.1466(0.0003) 0.8620 (0.0003) 0.1495 0.8577
BIND 0.1557(0.0007) 0.8528 (0.0008) 0.1556 0.8517
IntAct 0.1618(0.0004) 0.8466 (0.0004) 0.1623 0.8448
MINT 0.1665(0.0006) 0.8419 (0.0006) 0.1674 0.8398
Results are obtained using diffusion kernel (g=0.2) with Bayesian prior µ=0
and si =1 (for i ≥ 1). Results for the validation of random controls are mean
(standard deviation) of 10 independent runs.
Figure 2 ROC curves of the five PPI networks on random controls (A) and linkage intervals (B). AUC scores for the validation of random
controls are average of 10 independent runs.
Zhang et al. BMC Bioinformatics 2011, 12(Suppl 1):S11
http://www.biomedcentral.com/1471-2105/12/S1/S11
Page 6 of 10genes, and the scheme of handling missing data (setting
to zero) yield small Bayes factors for genes that are
absent from the network.
We then use the Bayesian regression approach to inte-
grate all the five PPI networks by extending the design
matrix to include gene proximities from multiple pro-
files. We repeat the leave-one-out cross-validation
experiments and present the results in Figure 4, from
which we observe clearly the better performance of the
proposed approach with the integrated use of multiple
PPI networks. The mean rank ratios for random con-
trols and linkage intervals are 0.1385 and 0.1380, respec-
tively, with AUC scores being 0.8702 and 0.8692,
respectively. In contrast, combining all genes and
interactions in individual PPI networks together to form
a large network (15,644 nodes and 77,332 edges) and
then applying CIPHER only yields mean rank ratios
0.1850 and 0.1876 (AUC scores 0.8230 and 0.8180) for
random controls and linkage intervals, respectively.
Directly applying the Bayesian regression approach to
the combined network yields mean rank ratios 0.1462
and 0.1469 (AUC scores 0.8624 and 0.8601) for random
controls and linkage intervals, respectively. Furthermore,
we also extract from the combined network interactions
that exist in at least two individual PPI networks and
obtain a high confident network (8,463 nodes and
28,617 edges). Focusing on genes in this network, we
extract from BioMart 2,219 associations between 1,441
Figure 3 Comparison with the CIPHER approach and the ordinary regression method. Subplots A and C illustrate mean rank ratios and
AUC scores against random controls, respectively. Subplots B and D illustrate mean rank ratios and AUC scores against linkage intervals,
respectively. Results for the validation of random controls are average of 10 independent runs (Variance not shown).
Figure 4 Performance of the integration method. Subplot A illustrates mean rank ratios for the integration method and individual PPI
networks. Subplot B illustrates AUC scores for the integration method and individual PPI networks. Results for the validation of random controls
are average of 10 independent runs (variance not shown).
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regression approach to this high confident network
yields mean rank ratios 0.1373 and 0.1380 (AUC scores
0.8717 and 0.8694) for random controls and linkage
intervals, respectively. Though these results are slightly
better than those of the Bayesian integration method,
the coverage of this high confident network is appar-
ently much lower than that of the Bayesian integration
approach. From these results, we conclude that the
Bayesian regression approach is effective in integrating
multiple PPI networks for prioritizing disease genes.
It is of interest to see how much individual PPI net-
works contribute to the integration approach. For this
purpose, we repeat the cross-validation experiments by
integrating every four data sources and see how the
exclusion of the remaining network affects the prioriti-
zation results. We find that all data sources have posi-
tive contributions to the integration approach, because
mean rank ratios increase and AUC scores drop when
any of the five data source is excluded. Results also sug-
gest the order of the data sources according to their
contributions (differences in cross-validation results) as
follows: HPRD > BIND > BioGRID > IntAct > MINT. It
is not surprising that HPRD contributes most to the
integration method, because HPRD has the largest cov-
erage and highest performance in previous validations.
It is also not surprising that MINT has the least contri-
bution, and IntAct has the second least contribution,
because both coverage and performance of these two
data sources are not high. However, it is not obvious
that BIND contributes more than BioGRID, because
individually, BioGRID has higher coverage and perfor-
mance than BIND. To understand this observation, we
analyze the relation between the five data sources and
find that Bayes factors calculated from HPRD and Bio-
GRID are highly correlated (Pearson’s correlation coeffi-
cient = 0.9770). Therefore, the removal of BioGRID,
when HPRD is presented, will not significantly affect the
performance of the integration method.
Finally, we study whether the integration approach is
biased toward well characterized genes, that is, genes
appearing in more data sources tend to have higher
ranks. We group all genes in a validation procedure into
10 categories according their ranks such that the i-th
category contains genes ranked at ((i - 1)×10%,i×10%].
For each category, we group genes according to the
number of PPI networks containing the genes such that
the j-th category contains genes appearing in exact j
networks. We then perform pair-wise Pearson’sc h i -
squared tests against the alternative hypothesis that fre-
quencies of genes appearing in different number of PPI
networks are different across different rank categories.
Results show that for the cross-validation experiment on
linkage intervals, the minimum p-value produced by the
series of chi-square tests is 0.0909, suggesting that we
cannot reject the null hypothesis. Similar results are
obtained for the cross-validation experiment on random
controls. We therefore conclude that the integration
approach is not biased toward well characterized genes.
In other words, genes appearing in more data sources
do not tend to have higher ranks.
Conclusions and discussion
In this paper, we propose a Bayesian regression
approach that relies on the linear relationship between
disease similarity and gene proximity to prioritize candi-
date genes. We show that gene proximity, as the diffu-
sion distance obtained from some PPI network, implies
disease similarity, and we perform a series of leave-one-
out cross-validation experiments to demonstrate the
effectiveness of the proposed approach. We show that
the Bayesian regression approach can achieve much
higher performance that an existing CIPHER approach
and the ordinary regression method. We also use the
proposed approach to integrate multiple PPI networks,
to achieve higher coverage while maintaining superior
performance. Our contribution in this paper therefore
lies in the following points: (1) systematic validation of
the assumption that gene proximity in a PPI network
implies disease similarity; (2) the Bayesian regression
approach that greatly improves the performance in
prioritizing disease genes, in comparison with a previous
CIPHER approach; (3) detailed analysis of the effective-
ness of five widely-used PPI networks in prioritizing dis-
ease genes; (4) a simple yet effective method to integrate
multiple PPI networks into a single prioritization model.
Certainly, our approach can be further studied from the
following aspects. First, the main reason of using conjugate
priors in the Bayesian regression model is to seed for ana-
lytic solutions and thus alleviate the computational burden
in the calculation of Bayesian factors. Although this for-
mulation shows great success, it is known that the specifi-
cation of prior is intrinsically complicated and subjective.
The main consideration here is that the posterior mean
and variance should not depend on the units in which the
disease similarities are measured and should also be invar-
iant to the shift of the response variable. Therefore, one
can consider the use of Jeffreys prior instead of the conju-
gate prior. By doing this, a Markov chain Monte Carlo
(MCMC) approach would be necessary in the calculation
of the marginal likelihood, and thus the computational
burden could be high.
Second, it is conceptually straightforward to extend
the Bayesian regression model to infer interactive effects
of multiple genes on a query complex disease. For
example, we can enumerate pair-wise combinations of
all candidate genes and calculate a Bayes factor for each
combination to infer the interactive effects of two genes
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come from the computational feasibility, because the
number of combinations of even a small number of can-
didate genes will be large.
Third, the means of dealing with missing data (setting
to zeros) in the proposed approach, though simple, is
kind of naïve. When more data sources are integrated,
the overlap of genes between data sources will typically
be lower, and thus a more effective method for dealing
with missing data is desired. One possible solution is to
interpolate missing data use the mean or median of
observed data. Another possible solution is to rank can-
didate genes using data sources individually and then
aggregate the ranks, as what is done in existing litera-
ture [6]. Both methods have their own advantages and
disadvantages, and a comprehensive comparison study is
necessary in order to obtain detailed understanding of
these possible solutions.
Finally, there have been a lot of large scale data pro-
duced by high-throughput techniques. To mention a
few, sequences of most human protein-coding genes are
known; mapping of human genes to Gene Ontology
(GO) is available; expression profile for most human
genes across various conditions has been obtained. How
to extend the proposed approach to integrate these data
sources will be one of the directions in our future work.
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